Clinical Study of Hypoxia-Stressed Bone Marrow Mononuclear Cell Transplantation to Treat Heart Diseases (CSHSBMMCTTHD)
Primary Purpose
Myocardial Infarction (MI) or Acute Myocardial Infarction (AMI)
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Hypoxia-stressed BMSCs transplantation to cure MI
Sponsored by
About this trial
This is an interventional treatment trial for Myocardial Infarction (MI) or Acute Myocardial Infarction (AMI)
Eligibility Criteria
Inclusion Criteria:
- Clinical diagnosis of acute Myocardial Infarction(within one month);
- Age under 65;
- Infarction related wall motion abnormality on echocardiography;
- Infarction related TIMI flow grades 3 on coronary angiography during cell injection;
- Informed consent;
Exclusion Criteria:
- Active infection, or hematopoietic malignancy;
- Patients have tumor or other lethal diseases;
- Informed refusal
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
BMSCs transplantation
No BMSCs transplantation
Arm Description
Outcomes
Primary Outcome Measures
Heart function
Secondary Outcome Measures
Full Information
NCT ID
NCT01234181
First Posted
November 3, 2010
Last Updated
November 3, 2010
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
1. Study Identification
Unique Protocol Identification Number
NCT01234181
Brief Title
Clinical Study of Hypoxia-Stressed Bone Marrow Mononuclear Cell Transplantation to Treat Heart Diseases
Acronym
CSHSBMMCTTHD
Official Title
Clinical Study of Hypoxia-Stressed Bone Marrow Mononuclear Cell Intracoronary Transplantation in Myocardial Infarction and Other Heart Diseases.
Study Type
Interventional
2. Study Status
Record Verification Date
November 2010
Overall Recruitment Status
Unknown status
Study Start Date
November 2010 (undefined)
Primary Completion Date
December 2012 (Anticipated)
Study Completion Date
December 2012 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study, is to determine the differences of clinical outcomes between hypoxic pre-treatment group and control group in bone marrow stem cell transplantation (BM-SCT) to treat acute myocardial infarction (AMI); and to evaluate the safety of both treatments. Heart failure patients underwent PCI treatment after AMI and with informed consent, are randomized allocation into hypoxic pre-treated BM-SCT group, normoxic pre-treated BM-SCT group, and control group. Cell resuspension is intracoronary injected into patients receiving coronary angiography, IL-6, CRP, TNF and BNP are detected; echocardiography, cardiac MRI and ECT are analyzed to evaluate heart function and alive myocardial cells. Holter's ECG monitor is employed to observe arrhythmia and embolism. We hypothesize that, by receiving hypoxic pre-treated BM-SCT, impaired heart function will be reversed in heart failure patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Infarction (MI) or Acute Myocardial Infarction (AMI)
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
BMSCs transplantation
Arm Type
Experimental
Arm Title
No BMSCs transplantation
Arm Type
Sham Comparator
Intervention Type
Procedure
Intervention Name(s)
Hypoxia-stressed BMSCs transplantation to cure MI
Intervention Description
Experimental group: intracoronary injection of 10^7 BMSCs Sham Comparator: inject the same volume saline
Primary Outcome Measure Information:
Title
Heart function
Time Frame
one year
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinical diagnosis of acute Myocardial Infarction(within one month);
Age under 65;
Infarction related wall motion abnormality on echocardiography;
Infarction related TIMI flow grades 3 on coronary angiography during cell injection;
Informed consent;
Exclusion Criteria:
Active infection, or hematopoietic malignancy;
Patients have tumor or other lethal diseases;
Informed refusal
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jian'an Wang, M.D, Ph.D
Organizational Affiliation
2nd Affiliated Hospital, School of Medicine at Zhejiang University
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
18374759
Citation
Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang JA, Wei L. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg. 2008 Apr;135(4):799-808. doi: 10.1016/j.jtcvs.2007.07.071.
Results Reference
background
PubMed Identifier
25755063
Citation
Hu X, Huang X, Yang Q, Wang L, Sun J, Zhan H, Lin J, Pu Z, Jiang J, Sun Y, Xiang M, Liu X, Xie X, Yu X, Chen Z, Tse HF, Zhang J, Wang J. Safety and efficacy of intracoronary hypoxia-preconditioned bone marrow mononuclear cell administration for acute myocardial infarction patients: The CHINA-AMI randomized controlled trial. Int J Cardiol. 2015 Apr 1;184:446-451. doi: 10.1016/j.ijcard.2015.02.084. Epub 2015 Feb 25.
Results Reference
derived
Learn more about this trial
Clinical Study of Hypoxia-Stressed Bone Marrow Mononuclear Cell Transplantation to Treat Heart Diseases
We'll reach out to this number within 24 hrs